Camber Spine Receives FDA Clearance for ENZA Zero Profile ALIF Device
Camber Spine Technologies received FDA 510(k) clearance to market the ENZA™ Zero Profile Anterior Interbody Fusion system. May 10, 2016
DePuy Synthes/JNJ Acquiring BioMedical Enterprises
DePuy Orthopaedics has acquired BioMedical Enterprises, a manufacturer of Nitinol orthopaedic implants for small bone fixation to treat bunions, hammertoes, hand/wrist deformities, etc. May 10, 2016
SpineGuard Launching PediGuard Threaded DSG Device
SpineGuard announced commercial launch of its PediGuard Threaded DSG™ (Dynamic Surgical Guidance) device. May 10, 2016
Histogenics Acquires Rights to NeoCart for the Japanese Market
Histogenics acquired development and commercialization rights to NeoCart® for the Japanese market from its partner, Purpose Co. NeoCart autologous cell therapy is designed to treat knee cartilage defects. May 10, 2016
Results from Study of Moximed’s Atlas Knee
Study results suggest that Moximed’s Atlas™ knee provided rapid, clinically-effective pain relief for patients with early knee OA in the pre-arthroplasty disease stage. May 09, 2016
Orthocell Gains Approval for Collagen Scaffold Study
Orthocell was granted ethical approval in Australia for a clinical study of a microfracture technique using the Celgro SMRT Graft collagen scaffold. May 04, 2016
Spinal Simplicity Gains Investor Support from Nueterra
Spinal Simplicity closed a financing round with an investment from Nueterra Capital. Funds will support U.S. launch of the Minuteman fusion device to treat low back pain. May 03, 2016
Medtronic Presents Results of 7-year Study on 2-level Prestige LP Cervical Disc
Seven-year follow-up data demonstrated favorable clinical outcomes and patient satisfaction for Medtronic’s 2-level Prestige LP™ cervical disc vs. 2-level ACDF. May 03, 2016
MEDTECH Announces First U.S. ROSA Spine Surgery
MEDTECH announced the first procedure using the ROSA™ Spine robot in the U.S. May 03, 2016
Bone Therapeutics Completes Recruitment in ALLOB Phase IIA Spinal Fusion Study
Bone Therapeutics completed recruitment for its ALLOB® allogeneic cell therapy Phase IIA spinal fusion study. The company will extend the trial to assess early onset of bone formation and fusion. May 03, 2016
